<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report on the outcomes of 53 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> secondary to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, autografted in first complete remission </plain></SENT>
<SENT sid="1" pm="."><plain>Five (9.4%) died from the procedure whereas hematological reconstitution occurred in <z:hpo ids='HP_0000001'>all</z:hpo> the remaining patients </plain></SENT>
<SENT sid="2" pm="."><plain>Forty patients (75%) relapsed, with 87.5% of the relapses occurring within 2 years of the autologous transplant </plain></SENT>
<SENT sid="3" pm="."><plain>With a median follow-up of 6.2 years, the median actuarial disease-free survival and overall survival were 8 and 17 months after autograft, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>Karyotype was the only prognostic factor for disease-free and overall survival </plain></SENT>
<SENT sid="5" pm="."><plain>The eight survivors (15%), including two patients with unfavorable or intermediate karyotype, remained in first complete remission 50+ to 119+ months after transplantation and are probably cured </plain></SENT>
</text></document>